Nymox Pharmaceutical Corp
NYMX
NYMX was delisted on the 6th of July, 2023.
1 hedge funds and large institutions have $4.13K invested in Nymox Pharmaceutical Corp in 2025 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
50% less funds holding
Funds holding: 2 → 1 (-1)
74% less capital invested
Capital invested by funds: $16K → $4.13K (-$11.8K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DDC
DF Dent & Co
Baltimore,
Maryland
|
-$10.9K |
NYMX Hedge Fund Activity: Q2 2025 in Review
1 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Nymox Pharmaceutical Corp (NYMX) for Q2 2025, worth a combined $4.13K — down 74% from $16K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of NYMX and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was DF Dent & Co, exiting entirely with an estimated $10.9K sold.
- 1 institutional investor held Nymox Pharmaceutical Corp (NYMX) as of Q2 2025, down from 2 in Q1 2025.
- Funds reported $4.13K of Nymox Pharmaceutical Corp stock for Q2 2025, down 74% quarter-over-quarter.
- 0 funds opened new Nymox Pharmaceutical Corp positions in Q2 2025 and 1 closed out, a net change of -1 holder.
- The largest Nymox Pharmaceutical Corp seller in Q2 2025 was DF Dent & Co, an estimated $10.9K sold.
Based on aggregated 13F filings for Q2 2025.